Literature DB >> 15778418

Potential utility of data-mining algorithms for early detection of potentially fatal/disabling adverse drug reactions: a retrospective evaluation.

Manfred Hauben1, Lester Reich.   

Abstract

The objective of this study was to apply 2 data-mining algorithms to a drug safety database to determine if these methods would have flagged potentially fatal/disabling adverse drug reactions that triggered black box warnings/drug withdrawals in advance of initial identification via "traditional" methods. Relevant drug-event combinations were identified from a journal publication. Data-mining algorithms using commonly cited disproportionality thresholds were then applied to the US Food and Drug Administration database. Seventy drug-event combinations were considered sufficiently specific for retrospective data mining. In a minority of instances, potential signals of disproportionate reporting were provided clearly in advance of initial identification via traditional pharmacovigilance methods. Data-mining algorithms have the potential to improve pharmacovigilance screening; however, for the majority of drug-event combinations, there was no substantial benefit of either over traditional methods. They should be considered as potential supplements to, and not substitutes for, traditional pharmacovigilance strategies. More research and experience will be needed to optimize deployment of data-mining algorithms in pharmacovigilance.

Mesh:

Year:  2005        PMID: 15778418     DOI: 10.1177/0091270004273936

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  7 in total

1.  Reply: The evaluation of data mining methods for the simultaneous and systematic detection of safety signals in large databases: lessons to be learned.

Authors:  Jonathan G Levine; Joseph M Tonning; Ana Szarfman
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

2.  Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions.

Authors:  Manfred Hauben; Sebastian Horn; Lester Reich
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

3.  Prospective data mining of six products in the US FDA Adverse Event Reporting System: disposition of events identified and impact on product safety profiles.

Authors:  Steven Bailey; Ajay Singh; Robert Azadian; Peter Huber; Michael Blum
Journal:  Drug Saf       Date:  2010-02-01       Impact factor: 5.606

4.  Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system.

Authors:  R Harpaz; W DuMouchel; P LePendu; A Bauer-Mehren; P Ryan; N H Shah
Journal:  Clin Pharmacol Ther       Date:  2013-02-11       Impact factor: 6.875

5.  Pneumothorax as an adverse drug event: an exploratory aggregate analysis of the US FDA AERS database including a confounding by indication analysis inspired by Cornfield's condition.

Authors:  Manfred Hauben; Eric Y Hung
Journal:  Int J Med Sci       Date:  2013-06-13       Impact factor: 3.738

6.  Signal detection and monitoring based on longitudinal healthcare data.

Authors:  Marc Suling; Iris Pigeot
Journal:  Pharmaceutics       Date:  2012-12-13       Impact factor: 6.321

7.  EUROmediCAT signal detection: an evaluation of selected congenital anomaly-medication associations.

Authors:  Joanne E Given; Maria Loane; Johannes M Luteijn; Joan K Morris; Lolkje T W de Jong van den Berg; Ester Garne; Marie-Claude Addor; Ingeborg Barisic; Hermien de Walle; Miriam Gatt; Kari Klungsoyr; Babak Khoshnood; Anna Latos-Bielenska; Vera Nelen; Amanda J Neville; Mary O'Mahony; Anna Pierini; David Tucker; Awi Wiesel; Helen Dolk
Journal:  Br J Clin Pharmacol       Date:  2016-07-07       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.